Helicobacter pylori and metabolic-associated fatty liver disease severity: a meta-analysis
Frontiers in Medicine · 17.06.2026 · 13
DOI: 10.3389/fmed.2026.1821076 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 17.06.2026. Verfasst von Lingyun Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Metabolic-associated fatty liver disease (MAFLD) is a global health concern. Observational evidence has suggested a possible relationship between Helicobacter pylori infection and MAFLD severity; however, severity-focused data remain inconsistent and methodologically heterogeneous.
Methods
We searched the international databases PubMed, Embase and Web of Science and the Chinese databases China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP) and Wanfang between January 2015 and December 2024. Observational studies reporting H. pylori status and MAFLD/non-alcoholic fatty liver disease (NAFLD) severity were included. Studies using NAFLD criteria were considered clinically comparable with MAFLD because they were conducted before the broad adoption of the MAFLD terminology and enrolled fatty liver disease populations defined by hepatic steatosis with metabolic features. Pooled odds ratios (ORs) were calculated using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment.
Results
Seven studies, comprising 11,168 participants (4,980 H. pylori -positive; 6,188 H. pylori -negative), were included. The overall random-effects analysis did not demonstrate a statistically significant association between H. pylori infection and MAFLD severity (pooled OR 1.47, 95% confidence interval [CI]: 0.83–2.59, p = 0.148 ; τ 2 = 0.1325), with substantial heterogeneity ( I 2 = 79.0%). In the non-invasive assessment subgroup, the pooled estimate was OR = 1.22 (95% CI: 0.95–1.57). The two biopsy-based studies showed high but highly imprecise individual estimates and were not interpreted as evidence of a stronger association. Geographic analysis showed an association only in Chinese populations (OR = 1.31, 95% CI: 1.15–1.49, I 2 = 0%).
Conclusion
Current evidence does not demonstrate a statistically significant overall association between H. pylori infection and MAFLD severity. A modest association was observed in Chinese studies, although biopsy-based evidence remains too imprecise for inference. Large-scale prospective studies with standardized assessment of active H. pylori infection and MAFLD severity are needed before causal or therapeutic conclusions can be drawn.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- Health Management Center, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Zhang, L., Zhang, Y., Qiao, L., Wu, R., He, F., Guan, Y., & Li, L. (2026). Helicobacter pylori and metabolic-associated fatty liver disease severity: a meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1821076
Vancouver
Zhang L, Zhang Y, Qiao L, Wu R, He F, Guan Y, et al. Helicobacter pylori and metabolic-associated fatty liver disease severity: a meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1821076
BibTeX
@article{Zhang2026,
author = {Zhang, Lingyun and Zhang, Yuexia and Qiao, Lei and Wu, Ruihan and He, Feng and Guan, Yuxin and Li, Lei},
title = {Helicobacter pylori and metabolic-associated fatty liver disease severity: a meta-analysis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1821076}
}
EUVIMED